United States: Federal Circuit Invalidates Prandin Patent Claim As Obvious

In its third look at the Novo Nordisk A/S patent related to Prandin®, in Novo Nordisk A/S v. Caraco Pharmaceutical Laboratories Ltd., the Federal Circuit affirmed the district court's finding that claim 4 of U.S. Patent No. 6,677,358 is invalid as obvious, but reversed the district court's finding that the patent is unenforceable due to inequitable conduct. This decision illustrates both the difficulty of sustaining a patent based on unexpected results and the difficulty of invalidating a patent based on inequitable conduct.

The Patent at Issue

The patent at issue in this case is U.S. Patent No. 6,677,358, which is listed in the FDA's Orange Book for Novo Nordisk's Prandin® repaglinide product. Claim 4 recites a "method for treating non-insulin dependent diabetes mellitus (NIDDM) comprising administering to a patient in need of such treatment repaglinide in combination with metformin."

As summarized by the Federal Circuit, "Type II diabetes can be treated with orally administered antidiabetic drugs ("OADs") in the form of monotherapy (a single OAD) or combination therapy (more than one OAD)." The drug repaglinide is an insulin secretagogue that works by stimulating insulin release from pancreatic beta cells, while the drug metformin is an insulin sensitizer that reduces insulin resistance by acting on the liver to reduce glucose production and thereby improve insulin sensitivity in muscle and fat tissues. The patent at issue arose from Novo Nordisk's discovery that combination therapy with both repaglinide and metformin achieved better results than monotherapy with either drug.

The District Court Decision

Caraco filed an Abbreviated New Drug Application in 2005, seeking FDA approval to market a generic version of Prandin®. Caraco's ANDA included a Paragraph IV certification asserting that the '358 patent was invalid or would not be infringed by its product. In response, Novo Nordisk brought suit under the Hatch-Waxman patent litigation framework, asserting claim 4 of the '358 patent. Caraco filed a counterclaim asserting invalidity and unenforceability. The district court conducted a bench trial, and held claim 4 invalid as obvious and that the patent was not enforceable because of inequitable conduct. Novo Nordisk appealed.


The parties did not dispute the district court's finding that Caraco had presented a prima facie case that "it was obvious to try combination therapy using metformin and repaglinide to treat Type II diabetes." In particular, "[i]t was apparently well-known in the art that two drugs having different mechanisms for attacking diabetes may be more effective than one, and so drugs were often tested in combination therapy after demonstrating effectiveness in monotherapy." Moreover, "[c]ombination therapy using insulin sensitizers and insulin secretagogues was common at the time, and metformin was the most widely-used insulin sensitizer as of the '358 patent's filing date." Thus, the issue before the court was whether the combination therapy achieved surprising and unexpected results, such as "synergistic" results." The district court found that it did not.

On appeal, Novo Nordisk lodged three main challenges to the district court decision, but the Federal Circuit was not persuaded by any of them.

First, Novo Nordisk asserted that "the district court misallocated the burden of persuasion in this case by forcing Novo to 'overcome' Caraco's 'prima facie' case of obviousness with evidence of unexpected results."

However, the Federal Circuit found that the district court properly had applied the presumption of validity by requiring Caraco to come forward with evidence of invalidity in the first instance. Only after finding "that Caraco's prima facie evidence, if unrebutted, would be sufficient to establish that the repaglinide/metformin combination was obvious to try, and that a person of ordinary skill in the art would have reasonably expected the combination would yield success in the form of beneficial, and even synergistic, results" did the district court "consider whether Novo's countervailing secondary consideration evidence of unexpected synergy (i.e., its "attempt to prove unexpected results") was sufficient to 'overcome' Caraco's prima facie case. Further, after evaluating "all evidence of unexpected synergy and commercial success," the district court "concluded that ... Caraco had shown by clear and convincing evidence that the combination was obvious."

Second, Novo argued that "even if the burdens were properly allocated in this case, Caraco's evidence insufficiently supported the court's ultimate obviousness findings."

The Federal Circuit disagreed. Novo Nordisk's position was based on unexpected results vis-à-vis "repaglinide's known efficacy in monotherapy." In contrast, the district court's analysis followed a three-step reasoning:
(1) the closest prior art [to the repaglinide/metformin combination] was combination therapy using metformin and a sulfonylurea;
(2) combination therapy using metformin and one of the sulfonylurea class of secretagogues was well known in the art to produce beneficial and even synergistic results in controlling glucose levels in Type II diabetes patients; [and]
(3) repaglinide was known as an insulin secretagogue having a similar mechanism of action to the sulfonylurea class of secretagogues.
The Federal Circuit found no error in the district court's analysis:

It is reasonable that an artisan seeking to combine a known insulin sensitizer (like metformin) with a new insulin secretagogue (like repaglinide) would base his expectations upon prior art sensitizer/secretagogue combinations.

Third, Novo urged that "the district court should have deferred to the examiner's original finding that the Sturis and Moses studies demonstrated unexpected synergy."

This argument was based on the recent Supreme Court decision in Kappos v. Hyatt, which the Federal Circuit found "has no relevance here." As explained by the court, "the initial determinations by the PTO in determining to grant the application are entitled to no deference as they would be in an appeal to this court under 28 U.S.C. § 1295(4)(A) or (absent new evidence) in a district court proceeding under 35 U.S.C. § 145. Rather, we treat the issued patent as having a presumption of validity that must be overcome by clear and convincing evidence. No decision of the Supreme Court or this court has ever suggested that there is an added burden to overcome PTO findings in district court infringement proceedings. ... Neither are we persuaded that the presence or absence of PTO findings on particular issues affects the basic presumption of validity."

Having rejected Novo Nordisk's challenges to the district court decision, the Federal Circuit affirmed the district court's finding of obviousness.

Inequitable Conduct

Caraco's inequitable conduct charges stemmed from statements and omissions in two expert declarations that had been submitted to the USPTO during prosecution of the '358 patent as evidence of unexpected results and the synergistic effect of the combination therapy. The district court found that the statements and omissions were "but for" material under the Federal Circuit's en banc decision in Therasense because the USPTO examiner had relied upon the declarations when deciding to withdraw the obviousness rejections. The Federal Circuit disagreed.

Although the court found that some of the statements and omissions at issue were "troubling," it could "not see how [the] omissions qualify as 'but for' material." The court emphasized:

This is not a case where a declarant hid adverse test results from the PTO in favor of more promising data selected post hoc. ... Nor is this a case where the declarant's omission expressly undermined his stated opinion. To the contrary, even after taking the omitted test protocol into account, the court specifically found that Dr. Sturis's conclusions on synergy had not been shown to be false.

Having found that the materiality prong of the inequitable conduct test was not satisfied, the Federal Circuit reversed the finding of inequitable conduct.

Speaking of Therasense, is the USPTO ever going to revise its guidance on the Duty of Disclosure to take this case into consideration?

The Back Story

Please see this article for a discussion of the Supreme Court decision which held that 21 USC § 355(j)(5)(C)(ii)(I) provided Caraco with a mechanism for challenging the use code that Novo Nordisk had provided in its Orange Book listing for Prandin®.

Please see this article for a discussion of the Federal Circuit decision which revised the district court's injunction requiring Novo Nordisk to replace the original use code with specific language.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on Mondaq.com.

Click to Login as an existing user or Register so you can print this article.

Similar Articles
Relevancy Powered by MondaqAI
McDermott Will & Emery
McDermott Will & Emery
In association with
Related Topics
Similar Articles
Relevancy Powered by MondaqAI
McDermott Will & Emery
McDermott Will & Emery
Related Articles
Related Video
Up-coming Events Search
Font Size:
Mondaq on Twitter
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
Email Address
Company Name
Confirm Password
Mondaq Topics -- Select your Interests
 Law Performance
 Law Practice
 Media & IT
 Real Estate
 Wealth Mgt
Asia Pacific
European Union
Latin America
Middle East
United States
Worldwide Updates
Registration (you must scroll down to set your data preferences)

Mondaq Ltd requires you to register and provide information that personally identifies you, including your content preferences, for three primary purposes (full details of Mondaq’s use of your personal data can be found in our Privacy and Cookies Notice):

  • To allow you to personalize the Mondaq websites you are visiting to show content ("Content") relevant to your interests.
  • To enable features such as password reminder, news alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our content providers ("Contributors") who contribute Content for free for your use.

Mondaq hopes that our registered users will support us in maintaining our free to view business model by consenting to our use of your personal data as described below.

Mondaq has a "free to view" business model. Our services are paid for by Contributors in exchange for Mondaq providing them with access to information about who accesses their content. Once personal data is transferred to our Contributors they become a data controller of this personal data. They use it to measure the response that their articles are receiving, as a form of market research. They may also use it to provide Mondaq users with information about their products and services.

Details of each Contributor to which your personal data will be transferred is clearly stated within the Content that you access. For full details of how this Contributor will use your personal data, you should review the Contributor’s own Privacy Notice.

Please indicate your preference below:

Yes, I am happy to support Mondaq in maintaining its free to view business model by agreeing to allow Mondaq to share my personal data with Contributors whose Content I access
No, I do not want Mondaq to share my personal data with Contributors

Also please let us know whether you are happy to receive communications promoting products and services offered by Mondaq:

Yes, I am happy to received promotional communications from Mondaq
No, please do not send me promotional communications from Mondaq
Terms & Conditions

Mondaq.com (the Website) is owned and managed by Mondaq Ltd (Mondaq). Mondaq grants you a non-exclusive, revocable licence to access the Website and associated services, such as the Mondaq News Alerts (Services), subject to and in consideration of your compliance with the following terms and conditions of use (Terms). Your use of the Website and/or Services constitutes your agreement to the Terms. Mondaq may terminate your use of the Website and Services if you are in breach of these Terms or if Mondaq decides to terminate the licence granted hereunder for any reason whatsoever.

Use of www.mondaq.com

To Use Mondaq.com you must be: eighteen (18) years old or over; legally capable of entering into binding contracts; and not in any way prohibited by the applicable law to enter into these Terms in the jurisdiction which you are currently located.

You may use the Website as an unregistered user, however, you are required to register as a user if you wish to read the full text of the Content or to receive the Services.

You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these Terms or with the prior written consent of Mondaq. You may not use electronic or other means to extract details or information from the Content. Nor shall you extract information about users or Contributors in order to offer them any services or products.

In your use of the Website and/or Services you shall: comply with all applicable laws, regulations, directives and legislations which apply to your Use of the Website and/or Services in whatever country you are physically located including without limitation any and all consumer law, export control laws and regulations; provide to us true, correct and accurate information and promptly inform us in the event that any information that you have provided to us changes or becomes inaccurate; notify Mondaq immediately of any circumstances where you have reason to believe that any Intellectual Property Rights or any other rights of any third party may have been infringed; co-operate with reasonable security or other checks or requests for information made by Mondaq from time to time; and at all times be fully liable for the breach of any of these Terms by a third party using your login details to access the Website and/or Services

however, you shall not: do anything likely to impair, interfere with or damage or cause harm or distress to any persons, or the network; do anything that will infringe any Intellectual Property Rights or other rights of Mondaq or any third party; or use the Website, Services and/or Content otherwise than in accordance with these Terms; use any trade marks or service marks of Mondaq or the Contributors, or do anything which may be seen to take unfair advantage of the reputation and goodwill of Mondaq or the Contributors, or the Website, Services and/or Content.

Mondaq reserves the right, in its sole discretion, to take any action that it deems necessary and appropriate in the event it considers that there is a breach or threatened breach of the Terms.

Mondaq’s Rights and Obligations

Unless otherwise expressly set out to the contrary, nothing in these Terms shall serve to transfer from Mondaq to you, any Intellectual Property Rights owned by and/or licensed to Mondaq and all rights, title and interest in and to such Intellectual Property Rights will remain exclusively with Mondaq and/or its licensors.

Mondaq shall use its reasonable endeavours to make the Website and Services available to you at all times, but we cannot guarantee an uninterrupted and fault free service.

Mondaq reserves the right to make changes to the services and/or the Website or part thereof, from time to time, and we may add, remove, modify and/or vary any elements of features and functionalities of the Website or the services.

Mondaq also reserves the right from time to time to monitor your Use of the Website and/or services.


The Content is general information only. It is not intended to constitute legal advice or seek to be the complete and comprehensive statement of the law, nor is it intended to address your specific requirements or provide advice on which reliance should be placed. Mondaq and/or its Contributors and other suppliers make no representations about the suitability of the information contained in the Content for any purpose. All Content provided "as is" without warranty of any kind. Mondaq and/or its Contributors and other suppliers hereby exclude and disclaim all representations, warranties or guarantees with regard to the Content, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. To the maximum extent permitted by law, Mondaq expressly excludes all representations, warranties, obligations, and liabilities arising out of or in connection with all Content. In no event shall Mondaq and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use of the Content or performance of Mondaq’s Services.


Mondaq may alter or amend these Terms by amending them on the Website. By continuing to Use the Services and/or the Website after such amendment, you will be deemed to have accepted any amendment to these Terms.

These Terms shall be governed by and construed in accordance with the laws of England and Wales and you irrevocably submit to the exclusive jurisdiction of the courts of England and Wales to settle any dispute which may arise out of or in connection with these Terms. If you live outside the United Kingdom, English law shall apply only to the extent that English law shall not deprive you of any legal protection accorded in accordance with the law of the place where you are habitually resident ("Local Law"). In the event English law deprives you of any legal protection which is accorded to you under Local Law, then these terms shall be governed by Local Law and any dispute or claim arising out of or in connection with these Terms shall be subject to the non-exclusive jurisdiction of the courts where you are habitually resident.

You may print and keep a copy of these Terms, which form the entire agreement between you and Mondaq and supersede any other communications or advertising in respect of the Service and/or the Website.

No delay in exercising or non-exercise by you and/or Mondaq of any of its rights under or in connection with these Terms shall operate as a waiver or release of each of your or Mondaq’s right. Rather, any such waiver or release must be specifically granted in writing signed by the party granting it.

If any part of these Terms is held unenforceable, that part shall be enforced to the maximum extent permissible so as to give effect to the intent of the parties, and the Terms shall continue in full force and effect.

Mondaq shall not incur any liability to you on account of any loss or damage resulting from any delay or failure to perform all or any part of these Terms if such delay or failure is caused, in whole or in part, by events, occurrences, or causes beyond the control of Mondaq. Such events, occurrences or causes will include, without limitation, acts of God, strikes, lockouts, server and network failure, riots, acts of war, earthquakes, fire and explosions.

By clicking Register you state you have read and agree to our Terms and Conditions